Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 17;20(1):26.
doi: 10.1186/s12883-020-1608-8.

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

Affiliations

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

Anna Santaella et al. BMC Neurol. .

Abstract

Background: Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.

Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.

Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).

Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Keywords: Biomarkers; Inflammation; Multiple system atrophy; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic (ROC) curve analysis of PD versus MSA. The combination of NFL levels with DNER and β-NGF in cerebrospinal fluid (solid black) does not yield better diagnosis accuracy than NFL alone (dashed dark grey) (AUC = 0.88 and 0.87 respectively, p value < 0.0001). Reference line in solid clear grey
Fig. 2
Fig. 2
Correlation of biomarkers with Parkinson’s disease (PD) progression. a. Correlation between MCP-1 and Hoehn and Yahr (HY) progression score; b. Correlation between MMP-10 and unified Parkinson’s Disease rating scale (UPDRS) progression score. Data were analyzed using Spearman correlation. Biomarker values are expressed as normalized protein expression. Right whisker plots represent median, interquartile range, minimum, maximum and outliers of disease score progression. Upper whisker plots represent median, interquartile range, minimum, maximum and outliers of the protein marker levels in cerebrospinal fluid of PD patients. Rho was > 0.600 and p value < 0.01 for both correlations

Similar articles

Cited by

References

    1. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896–912. doi: 10.1016/S0140-6736(14)61393-3. - DOI - PubMed
    1. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004;56(4):532–539. doi: 10.1002/ana.20226. - DOI - PubMed
    1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211. doi: 10.1016/S0197-4580(02)00065-9. - DOI - PubMed
    1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75–86. doi: 10.1016/S1474-4422(05)70285-4. - DOI - PubMed
    1. Hoglinger GU, Kassubek J, Csoti I, Ehret R, Herbst H, Wellach I, et al. Differentiation of atypical Parkinson syndromes. J Neural Transm (Vienna) 2017;124(8):997–1004. doi: 10.1007/s00702-017-1700-4. - DOI - PubMed

LinkOut - more resources